Nonsteroidal antlinflammatory drugs (NSAIDs), have cancer preventive and tumor regressive effects in the human colon. They lower the incidence of and mortality from colorectal cancer and sulindac reduces the number and size of polyps in patients with familial adenomatous polyposis.
Introduction
Nonsteroidal antiinflammatory drugs (NSAIDs)' are among the most commonly used medications. Their use dates back to 1875 when sodium salicylate was given to patients with rheumatic fever as an anti-pyretic (1) . They are currently utilized in a 1 . Abbreviations used in this paper: cdks, cyclin-dependent kinases; FAP, familial adenomatous polyposis; NSAIDs, nonsteroidal antiinflammatory drugs.
variety of clinical situations and are often administered for long periods of time, in certain cases for many years. Indications requiring such long-term use include the prevention of myocardial infarction and cerebrovascular disease and the treatment of chronic inflammatory diseases such as rheumatoid arthritis.
Several epidemiological studies have demonstrated an association between the long-term consumption of NSAIDs and a reduced incidence of and mortality from colon cancer (e.g., most recently, [2, 3] ). Sulindac (Clinoril®) has been shown to reduce the number and size of colonic and rectal adenomatous polyps in patients with familial adenomatous polyposis (FAP) (4, 5) , although this effect may not be permanent (6) . In addition, animal studies have shown that NSAIDs have anti-neoplastic effects in the colon. Aspirin (7) , sulindac (8) , piroxicam (9) , and indomethacin (10) all reduce the number and size of tumors arising in the colon of rodents administered colonic carcinogens such as dimethyl-hydrazine or azoxymethane.
Because sulindac has such a marked anti-tumor effect, regressing established adenomatous polyps in patients with FAP, it is important to understand the mechanisms mediating this phenomenon. These theoretically could include the regulation of the dynamics of cell proliferation in the colonic mucosa. This hypothesis is supported by the work of Bayer et al. (11, 12) , who demonstrated that indomethacin reversibly inhibits the proliferation of human fibroblasts and rat hepatoma cells and arrests them in the GI phase of the cell cycle.
Over the past several years, some of the molecular events governing progression through the various phases of the eukaryotic cell division cycle have been elucidated. Two families of proteins have been shown to play a central role in regulating the major transition points of the cell cycle in all eukaryotic organisms: the cyclins and the cyclin dependent kinases (cdks), (see references 13 and 14 for recent reviews). The cyclins comprise a group of regulatory proteins that share stretches of amino acid sequence homology. The cdks are a family of serine/ threonine protein kinase subunits that associate with cyclins before their activation in discrete phases of the cell cycle (13, 14) . All cdks share amino acid sequence homology with p34CdC2, the prototypical molecule of this family. Recently, another family of proteins that play a key role in cell cycle regulation, the cyclin-dependent kinase inhibitors, have been described which interact with cdks or cyclin-cdk complexes to inhibit cdk catalytic activity (15).
The cdks that participate in regulating cell cycle progression include: (a) p34cdc2 which, in concert with the A-and B-type cyclins, controls the G2/M transition (16) (17) (18) (19) ; (b) p33cdu, which regulates the GI/S transition (16, 18, 20) in association with cyclin E (21) (22) (23) (24) ; and (c) p34CIl4 (25, 26) and p40Ccdk6 (27) which, in conjunction with the D-type cyclins (Dl, D2, or D33), control progression through GI (28) . In most proliferating bly throughout the cell cycle (29, 30) . Thus cdk activity, and therefore advancement through the cell cycle, is regulated in part by the distinctive periodic expression patterns of the different cyclins.
Since indomethacin has been shown to reduce the proliferation and alter the cell cycle of noncolonic cells ( 11, 12, 31) , it is conceivable that NSAIDs affect colonic epithelial cells in a similar fashion. Therefore, we studied the effect of sulindac and sulindac sulfide, clinically important compounds in the chemoprevention of colon cancer, on the proliferation and the cell cycle of HT-29 colon adenocarcinoma cells.
As sulindac sulfide is considered the active metabolite of sulindac, we elected to use concentrations of sulindac sulfide that could conceivably be achieved in the colon in vivo. A large fraction of sulindac is converted to sulindac sulfide in the colon by colonic bacteria (32) . Therefore, high lumenal concentrations of sulindac sulfide are achieved in the colon (33) . In addition, animal studies have shown that sulindac sulfide is concentrated in the mucosa of the colon at levels several-fold higher than in the serum (34) . Colonic epithelial cells can be exposed to concentrations up to 20-fold higher than those in serum (33) ; serum levels of sulindac sulfide are about [10] [11] [12] [13] [14] [15] MM when sulindac is given orally at doses which regress polyps in FAP patients (35, 36) . Sulindac, was used at concentrations several times higher than sulindac sulfide to see if the parent compound could mimic its effects.
It is also possible that the mechanisms responsible for the anti-proliferative effects of the NSAIDs on cultured cells is multifactorial. Apoptotic cell death is another mechanism that could contribute to reduced cell growth. Apoptosis has been the focus of intense scrutiny and has become better understood at the molecular genetic level (for recent reviews see references 37-39). It is a genetically determined and evolutionarily conserved process that occurs in a variety of physiological and pathophysiological contexts including: (a) the elimination of self-reactive immune cells; (b) embryonic tissue development; and (c) tumorigenesis. Therefore, we also examined whether these compounds caused apoptosis in HT-29 colon cancer cells.
Methods
Cell lines. The human colon adenocarcinoma cell line HT-29 (ATCC HTB 38) 50 Mg of total protein from control and drug-treated samples were resolved on 10% SDS-PAGE gels along with prestained protein molecular weight standards (Sigma). Gels were then Western blotted onto PVDF membranes (Polyscreent3', Dupont-NEN, Boston, MA) (as described in Harlow and Lane [42] ). Upon completion of the transfer, the membranes were blocked with 5% milk (Carnation nonfat dry milk; Carnation Co., Los Angeles, CA) in TBS/0.05% Tween-20 (TBS-T) for a minimum of 2 h at room temperature. Membranes were washed with two changes of TBS-T, then reacted with the primary antibodies at a 1:1,000 dilution in 5% milk/TBS-T for 1 h at room temperature. Following primary antibody incubation, the blots were washed four times with TBS-T, and then incubated with the secondary antibody, a peroxidase-conjugated goat anti-rabbit antibody (GIBCO BRL) diluted 1:5,000 in 5% milk/TBS-T for a minimum of 1 h at room temperature. Then, after additional washing with TBS-T, the cdk proteins were detected with a chemiluminescence assay system (Renaissance3'; Dupont-NEN). After the specific proteins were visualized, the blots were stained with 0.1% India ink in TBS with 0.3% Tween-20 to verify that equal amounts of total protein were present in all of the lanes (42 Apoptosis. The cells were evaluated for evidence of apoptosis by three different assays: (a) measurement of the DNA content of cells by propidium iodide staining and FACS analysis (43, 44) , to detect a subdiploid peak of DNA, indicative of the DNA fragmentation occurring with apoptosis; (b) acridine orange staining to identify cellular morphologic changes characteristic of apoptosis (45); and (c) agarose gel electrophoresis of genomic DNA to detect the DNA degradation associated with apoptosis (46) . Acridine orange staining. Single cell suspensions of control and drug-treated HT-29 cells in PBS/BSA were fixed with 70% ethanol and frozen at -20°C for at least 30 min. They were washed and resuspended in PBS and treated with ice-cold 0.1% Triton X-100, 0.08 N HCl, and 0.15 M NaCl. The cells were then stained with 20 tZM acridine orange (Sigma) in a phosphate-citric acid buffer (pH 6) containing 1 mM EDTA and 0.15 M NaCl. The suspension of stained cells was centrifuged at 750 g and cells were then resuspended in PBS. One drop of this suspension was placed on a microscope slide and the cells were evaluated by UV fluorescence microscopy. The morphologic criteria used to quantify the fraction of apoptotic cells on these slides included the presence of: (a) cytoplasmic and nuclear shrinkage; (b) chromatin condensation; and (c) cytoplasmic blebbing with maintenance of the integrity of the cell membrane (zeiosis) (37). The percentage of apoptotic cells among all of the cells present on the slide was determined by counting 10 randomly selected high-power fields.
For fluorescence microscopy, 50,000 freshly harvested cells from control or drug-treated dishes were applied to glass slides by centrifugation at 1,000 rpm in a cytospin well (Cytospin 2; Shandon Inc., Pittsburgh, PA) for 5 min. The slides were fixed by immersion in acetic acid/ethanol (1:9, vol/vol) for at least 20 min. Upon drying, the slides were treated with HBSS, and stained with acridine orange as above. Following several washes with HBSS, the cells were examined with a UV fluorescence microscope and photographed (Labophot, Nikon Inc. Fig. 3 a) . Cells treated with 150 MM sulindac sulfide (Fig.  3 b) for 72 h also grew in groups, but developed elongated cellular processes and assumed unusual shapes. Treatment with 200MM sulindac sulfide for 72 h induced striking morphological changes in these cells. As demonstrated in Fig. 3 c, these cells grew as small, single cells, often separated from neighboring cells, and displayed prominent long filamentous processes. These processes were similar to, but more prominent than, those seen following treatment with lower concentrations of sulindac sulfide (Fig. 3 b) . In addition, cells treated with 200 1iM sulindac sulfide developed small, round, and highly refractile intracellular bodies distributed throughout their cytoplasm (Fig. 3  c) . These changes were evident as early as 12 to 24 h after incubation of the HT-29 cells with sulindac sulfide (data not shown).
Sulindac treatment resulted in similar, if not identical, morphological changes in these cells, but at higher concentrations than were required to see an effect with sulindac sulfide. Sulindac 1,200 MM (Fig. 3 g) induced the alterations in cell morphology similar to those seen with 200 1iM sulindac sulfide (Fig. 3  c) . In addition, sulindac 600 uM (Fig. 3 f ) induced changes similar to those seen at the 150 [tM concentration of sulindac sulfide (Fig. 3 b) . These morphological changes were also evident as early as 12 to 24 h after incubation with sulindac (data not shown). In addition, there was virtually no difference in the morphology of cells incubated in medium with (Fig. 3 a) or without (Fig. 3 e) supplemental DMSO at a concentration of 0.6%.
The effect of sulindac and sulindac sulfide on the proliferation and morphology of (Fig. 3 h) .
Sulindac sulfide also had a reversible effect on HT-29 cell proliferation and morphology. As shown in Fig. 2 (Fig. 3 d) . The morphologic alterations were rapidly re-
versed (data not shown), often 24 h after removal of sulindac sulfide. 6 ). Fig. 7 shows DNA content frequency histograms from control and sulindac sulfide-treated cells after 72 h of incubation. The changes in the cell cycle phase distribution in response to sulindac sulfide are also clearly visible in this figure which also demonstrates the appearance of a sub-diploid peak in the sulindac sulfide-treated cells ( Fig. 7 middle and see below). Sulindac-treated cells did not manifest such a sub-diploid peak after 72 h of incubation (data not shown). Sulindac and sulindac sulfide reduce the level ofp34"c2, p33dk2, and p34cd 4 in HT-29 colon cancer cells Since high concentrations of sulindac and sulindac sulfide had such a marked effect on the cell cycle distribution of HT-29 colon cancer cells, we evaluated potential molecular mechanism(s) related to this effect. Inhibition of the activity of selected cyclin-dependent kinases, has been shown in many systems to induce cell cycle arrest (18) . We wished to determine whether drug treatment could alter the levels and activity of certain cdks that are critical for the regulation of cell cycle progression in eukaryotic cells. Therefore, the relative levels of the cdks, p34cdc2 and p33cdWI, and p34'4 were determined in extracts prepared from control, sulindac-, and sulindac sulfidetreated cells by Western blot. As illustrated in Fig. 8 The cell cycle phase distribution was measured in parallel from an aliquot of the cells collected in this experiment. As is demonstrated in Fig. 8 (bottom) , the expected alteration in the cell cycle phase distribution (high GO/GI and low S and G2/M phases) was also observed with sulindac 1,200 MLM and sulindac sulfide 175 MzM. As is shown in Fig. 8 (600 1iM) and sulindac sulfide (100 AM) resulted in minimal, if any, reduction in levels of p34cdc2, p33', or p34cdk4 ( Fig.   8, a-c) . In addition, as expected, the lower concentrations of these compounds did not affect the cell cycle phase distribution of these cells (Fig. 8, bottom, Figs. 5 and 6) . Therefore, the changes in the abundance of the cdk proteins were noted only when sulindac and sulindac sulfide induced an effect on the cell cycle in these cells.
To confirm that equal amounts of total protein were loaded in each of the lanes on these blots, after they were probed with the appropriate antibodies, they were treated with India ink to visualize the total protein content in all of the lanes. There were approximately equal amounts of total protein in all of the lanes of these membranes, including the lanes where the cdks were profoundly reduced (data not shown). These concentrations also reduced the proliferation and altered the morphology and cell cycle phase distribution of these cells (Fig. 9, bottom) . There was no effect on the associated histone Hi kinase activity of p34cdc2 (Fig. 9 a) or p33Cdk2 (Fig. 9 b) upon treatment with sulindac or sulindac sulfide at lower concentrations that had minimal, if any, effect on cdk levels on Western blot (Fig. 8) or on the cell cycle phase distribution of these cells (Fig. 9, bottom) . To exclude the possibility that these compounds directly inhibit the catalytic activity of p34c"c2 and p33', sulindac (1,200 ILM) and sulindac sulfide (175 tiM) were added to the p34 12 and p33' IP-kinase assays from lysates of HT-29 cells incubated in control medium for 72 h. There was no difference in the associated histone H1 kinase activity in these reactions compared to those without the compounds added to the kinase buffer (data not shown).
Hence, in a concentration-dependent manner, though nonlinear and restricted to the higher concentrations tested, sulindac and sulindac sulfide: (a) induced a significant shift in the cell cycle phase distribution towards Go/GI; and (b) reduced the levels of three critical cell cycle regulators, p34C C2, p33Cdk2, and p34d4 in HT-29 colon adenocarcinoma cells. Furthermore, the reduction in the levels of p34c1C2 and p33 k was also accompanied by a reduction in their catalytic activity. On a molar basis, sulindac sulfide was six times more potent than sulindac in bringing about these effects. These data indicate that critical cell cycle transition points, GI -+ S, G2 --M and possibly the progression through GI were profoundly inhibited by treatment with these compounds. Given the known significance of inhibiting cdk function on cell cycle progression (17, 18) , these results suggest that high concentrations of sulindac and sulindac sulfide increase the fraction of cells with Go/GI DNA content by arresting them in the GI or Go phase of the cell cycle through an effect on the molecular components that regulate cell cycle transitions.
Sulindac sulfide induces apoptosis in HT-29 colon cancer cells and HL-60 promyelocytic leukemia cells Treatment of HT-29 colon cancer cells with sulindac and sulindac sulfide reduced the net cell accumulation over time. Both compounds also arrested a substantial fraction of these cells in the Go or GI phase of the cell cycle. This phenomenon could explain, in part, the anti-proliferative effect of high concentrations of these compounds on cultured HT-29 cells. However, we suspected that the anti-proliferative effect of higher concentrations of sulindac sulfide, in particular, might be multifactorial because a large percentage of HT-29 cells treated with high concentrations of sulindac sulfide developed less than a diploid amount of DNA on FACS analysis (Fig. 7 b) . This sub-diploid peak in DNA content correlates with the morphologic and biochemical hallmarks of apoptosis (43, 44) . Therefore, we sought to determine whether sulindac sulfide treatment induces apoptosis in HT-29 colon cancer cells.
HT-29 cells were treated with either control medium or sulindac sulfide-(100 tIM, 150 ,1M, or 200 kM) supplemented medium for 72 h after which their morphology was evaluated by acridine orange staining. Sulindac sulfide, at concentrations that altered the cell cycle distribution of these cells, induced morphological hallmarks of apoptosis. As is evident in Fig. 10 , a high fraction of 175 uM sulindac sulfide-treated cells exhibit nuclei with condensed and fragmented chromatin. In addition, the plasma membrane remained intact around these aberrant nuclei and, in some cells, the condensed DNA appeared to bud off from the remainder of the cell. 10 ) and with the height of the sub-diploid peak in DNA content noted on FACS analysis (Fig. 7 and data not shown). Fig. 11 b also shows genomic DNA prepared in the same fashion from HL-60 cells treated for 4 h with either control medium or sulindac sulfide-(50-200 ttM) supplemented medium. The HL-60 cells developed a nucleosomal ladder pattern of DNA degradation, considered distinctive of apoptosis, on treatment with higher concentrations of sulindac sulfide. A characteristic ladder pattern was also observed in sulindac sulfide-treated HT-29 cells when greater amounts of DNA were resolved on agarose gels (Fig. 11 c) .
Thus, sulindac sulfide induced apoptosis in HT-29 colon adenocarcinoma cells in three assays commonly used to demonstrate this phenomenon.
Discussion
Our findings demonstrate that the NSAIDs sulindac and sulindac sulfide have profound effects on HT-29 colon adenocarcinoma cells in vitro. These compounds reduce the proliferation rate of these cells, cause changes in their morphology, induce them to accumulate in the GO/GI phase of the cell cycle, and induce cell death by apoptosis. These responses are time-dependent, reversible, and are prominent at the higher concentrations of sulindac and sulindac sulfide tested. The response of these cells to sulindac is not due to extensive conversion to sulindac sulfide in the culture medium during incubation with the HT-29 cells.
Our findings that sulindac and sulindac sulfide have profound anti-proliferative effects on HT-29 colon adenocarcinoma cells are in agreement with previous studies demonstrating that many of the NSAIDs inhibit the proliferation of nonintestinal cultured cell lines (11, 12, 31, (48) (49) (50) (51) . For example, sulindac sulfide, one of the compounds we studied, inhibited the accumulation of lapine chondrocytes (51) . Sulindac sulfide and, to a lesser degree, sulindac inhibit cyclooxygenase (prostaglandin synthetase) activity (52) . However, whether inhibition of eicosanoid synthesis plays a role in the effect of sulindac or sulindac sulfide on cell proliferation remains unresolved (12, 53) .
We also report that sulindac and sulindac sulfide cause a reversible change in the morphology of HT-29 cells. These morphological changes, long cytoplasmic extensions and intracytoplasmic vesicles, were similar to those reported by Neupert cin (48) . It is noteworthy that, in our experiments, the morphological changes caused by sulindac and sulindac sulfide occuffed over the concentration ranges which also reduced the proliferation of the HT-29 cells.
Our study demonstrates that, in addition to reducing the proliferation and altering morphology, sulindac and sulindac sulfide alter the cell cycle distribution of HT-29 cells. Sulindac and sulindac sulfide caused an increase in the proportion of cells in the GO/GI phase and a decrease in the percentage of cells in the S and G2/M phases. This effect was reversible and occurred at the higher end of the concentration range that altered cell morphology and inhibited cell proliferation. Previous studies on nonintestinal cells have described a similar cell cycle effect in response to indomethacin treatment (11, 12, 31) . In our work, the combination of cell type (colon) and class of NSAID (sulindac and sulindac sulfide) is important because of the striking human data that show the colon to be a key target for the action of these drugs (3) (4) (5) .
The changes in the cell cycle phase distribution of HT-29 cells in response to sulindac and sulindac sulfide treatment, were accompanied by profound reductions in the level and activity of key proteins that regulate progression through the cell cycle. Sulindac and sulindac sulfide reduced the level of cdks (p34CdC2, p33Cdk2, p34 4), and also the in vitro kinase activity of p34 C2 and p33Cdk2; we did not measure the in vitro kinase activity of p34Cdk4 in this study. The relative deficiency in the activity of these key proteins may contribute to the accumulation of these cells in the GO/GI phase following treatment with sulindac and sulindac sulfide. The reduced levels of these proteins may explain their reduced activity. However, the possibility that cdk inhibitors also play a role in this phenomenon has not yet been ruled out (15). The mechanisms through which these compounds influence the levels of these cdk proteins remains unknown. It is conceivable that exogenous sulindac and sulindac sulfide produce this effect by influencing signaling pathways in these cells that control the levels of these proteins. Regardless of the exact molecular mechanism involved, the reduction in the level and activity of certain cdks may be important for the anti-proliferative effect of these compounds.
Sulindac and, more potently, sulindac sulfide induce apoptosis in HT-29 colon adenocarcinoma cells. To our knowledge, this is the first report to document that a class of NSAIDs can induce cell death by apoptosis in colonic epithelial cells. Apoptosis in response to sulindac sulfide treatment was documented by showing the appearance of: (a) morphological changes characteristic of apoptosis; (b) a sub-diploid peak of DNA content on FACS analysis; and (c) genomic DNA degradation. Evidence that apoptosis was induced by sulindac was based on the detection of morphological changes only; no subdiploid peak was noted on DNA content frequency histograms. The apoptosis induced by these compounds likely also contributes to their effect on the growth rate of HT-29 cells. Furthermore, additional studies we have performed, which will be reported elsewhere, have shown that sulindac sulfide induces apoptosis in other colon cancer cell lines such as HCT-15 (54) .
Under the influence of higher concentrations of sulindac and sulindac sulfide, the cell cycle distribution, the activity of cell cycle kinases and the rate of apoptosis all changed in parallel. These responses occurred at concentrations of sulindac above 600 jLM and of sulindac sulfide above 100 MM. However, the correlation between the effect of these compounds on cell proliferation and on these responses was not as strict at lower concentrations. For (35, 36) . Pharmacological studies have demonstrated that colon tissue levels of sulindac sulfide far exceed those in plasma; tissue to plasma ratios in the colon are in the range of 10-20 (33, 34) . In addition, since approximately half of the sulindac sulfide in plasma originates from sulindac via bacterial metabolism in the colon (32) , high concentrations of this compound reaches colon cells through the lumen. As a result of this analysis through lumenal exposure and tissue accumulation, it is conceivable that high concentrations of sulindac sulfide, in the range that produced the cellular effects we observed in vitro, can be achieved in the colon of humans. Finally, since both compounds are highly protein bound (1) , the effective concentration (or concentration of free molecules) in the culture dishes is really unknown.
Sulindac, in humans, reaches plasma levels of 10 uM but, in contrast to sulindac sulfide, it does not accumulate in colonic tissue (34) . Thus, it is less likely that sulindac achieves tissue levels comparable to those that were effective in this study (1, 200 MtM). However, the possibility that high lumenal levels are reached in the microenvironment of the colonic crypts cannot be excluded. Overall, by virtue of its reported tissue accumulation and in vitro potency, sulindac sulfide appears the more likely of the two compounds responsible for the biological changes that have been observed with sulindac in vivo.
It is also conceivable that apoptosis might occur in the human colon in response to sulindac. There is limited histologic evidence that treatment with mefanamic acid and diclofenac can induce apoptosis in the human colon. Lee has shown induction of apoptosis in the crypts of colorectal biopsy specimens from patients who developed gastrointestinal symptoms in response to these NSAIDs (59) . The apoptosis noticed in his study, uncharacteristically however, was associated with an inflammatory cell infiltration in the lamina propria and the crypts.
Apoptosis in the gut mucosa may be relevant to the pathogenesis of gastrointestinal malignancies. Qualitative differences in apoptosis in the small intestine, as compared with that in the colon and rectum, may help to explain the disparate incidence rates of adenocarcinoma between these organs (60) . Also of interest, sodium butyrate, a short-chain fatty acid generated in high concentrations in the colon by bacterial fermentation of dietary fiber (61) 
